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The renin-angiotensin system (RAS) is an essential regulator
of blood pressure and fluid homeostasis. A complete and
functional RAS exists in the brain and comprises all
necessary precursors and enzymes required for the synthesis
and metabolism of its components (Veerasingham and
Raizada 2003; Xu et al. 2011). In addition to the known
effector angiotensin (Ang) II, the heptapeptide Ang-(1–7) is a
biologically active component of the RAS which limits the
pressor and proliferative effects of Ang II. Thus, Ang-(1–7)
produces vasodilation, natriuresis and diuresis, inhibits
angiogenesis and cell growth (Ferrario et al. 2010; Ferreira
et al. 2010; Xu et al. 2011).
At the central level, Ang-(1–7) facilitates the baroreflex
control of blood pressure and acts at cardioregulatory
brain areas, such as hypothalamic and brainstem nuclei,
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Abstract
As angiotensin (Ang) (1–7) decreases norepinephrine (NE)
content in the synaptic cleft, we investigated the effect of Ang-
(1–7) on NE neuronal uptake in spontaneously hypertensive
rats. [3H]-NE neuronal uptake was measured in isolated hy-
pothalami. NE transporter (NET) expression was evaluated in
hypothalamic neuronal cultures by western-blot. Ang-(1–7)
lacked an acute effect on neuronal NE uptake. Conversely,
Ang-(1–7) caused an increase in NET expression after 3 h
incubation (40 ± 7%), which was blocked by the Mas receptor
antagonist, a PI3-kinase inhibitor or a MEK1/2 inhibitor sug-
gesting the involvement of Mas receptor and the PI3-kinase/
Akt and MEK1/2-ERK1/2 pathways in the Ang-(1–7)-stimu-
lated NET expression. Ang-(1–7) through Mas receptors
stimulated Akt and ERK1/2 activities in spontaneously
hypertensive rat neurons. Cycloheximide attenuated Ang-(1–
7) stimulation of NET expression suggesting that Ang-(1–7)
stimulates NET synthesis. In fact, Ang-(1–7) increased NET
mRNA levels. Thus, we evaluated the long-term effect of Ang-
(1–7) on neuronal NE uptake after 3 h incubation. Under this
condition, Ang-(1–7) increased neuronal NE uptake by
60 ± 14% which was blocked by cycloheximide and the Mas
receptor antagonist. Neuronal NE uptake and NET expression
were decreased after 3 h incubation with an anti-Ang-(1–7)
antibody. Ang-(1–7) induces a chronic stimulatory effect on
NET expression. In this way, Ang-(1–7) may regulate a pre-
synaptic mechanism in maintaining appropriate synaptic NE
levels during hypertensive conditions.
Keywords: angiotensin-(1–7), hypertension, Mas receptor,
norepinephrine transporter, norepinephrine uptake.
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contributing to blood pressure regulation (Xu et al. 2011).
This action may result from its activity on neurotransmitter
release; that is, the peptide not only diminishes hypothalamic
norepinephrine (NE) release but also blocks the stimulatory
effect of Ang II on this mechanism (Gironacci et al.
2004a,b). In addition, Ang-(1–7) stimulates the degradation
of L-tyrosine hydroxylase as well as inhibits its enzymatic
activity in hypothalami and neuronal cultures from sponta-
neously hypertensive ratas (SHR), reducing in consequence
NE biosynthesis (Lopez Verrilli et al. 2009). Altogether,
these effects lead to a decrease in NE levels at the synaptic
cleft, thus contributing to blood pressure regulation.
Synaptic neurotransmission requires the precise control of
the duration and the magnitude of neurotransmitter action at
specific molecular targets. Uptake of monoamine neurotrans-
mitters into pre-synaptic terminals through the transporters is
the main mechanism for monoaminergic neurotransmission
ending. NE transporter (NET) regulates noradrenergic
signaling in central and peripheral nervous systems by
mediating the clearance of NE (Eisenhofer 2001; Torres
et al. 2003; Bönisch and Brüss 2006;2 Kvetnansky et al.
2009). Thus, changes in the activity of NET should have a
significant impact on the concentration and duration of NE
present in the synaptic cleft and consequently alter NE
signaling. In this way, NET is essential for a fine-tuned
control of sympathetic activity. In fact, alterations in NE
clearance and NET density are observed in cardiovascular
diseases and brain disorders (Bönisch and Brüss 2006;
Kvetnansky et al. 2009). Based on previous reports that
Ang-(1–7) diminishes NE release and synthesis in hypotha-
lami from SHR (Gironacci et al. 2004a; Lopez Verrilli et al.
2009) we hypothetized that Ang-(1–7) elicits an stimulatory
effect on neuronal NE removal. Thus, our aim was to
investigate the effect of Ang-(1–7) on neuronal NE uptake
and NET expression centrally in SHR rats. In addition, the
mechanism of action of Ang-(1–7) on NET expression was
also evaluated. We carried out our study in SHR because we
previously reported that Ang-(1–7) does not affect neuronal
NE uptake in normotensive rats (Gironacci et al. 2000). In
addition, it has been shown that Ang-(1–7) effects are
enhanced in situations of Ang II overactivity as in hyper-
tension (Ferrario et al. 1997).
Methods
Materials
Horse serum and Dulbecco’s modified Eagle’s medium were
purchased from Invitrogen (Carlsbad, CA, USA). Deoxiribonuc-
lease I (Dnase I), hydrocortisone, pargyline, desipramine, actimo-
mycin D, cycloheximide and cytosine arabinoside were from Sigma
Chemical Co. (St Louis, MO, USA). Losartan was from Dupont
(Boston, MA, USA). PD123319 was a gift from Dr Jack Hodges at
Parke Davis (Detroit, MI, USA). LY294002 was from Cell
Signaling (Beverly, MA, USA) and U0126 was from Calbiochem
(Gibbstown, NJ, USA). Ang-(1–7) and [D-Ala7]-Ang-(1–7) were
synthesized in our laboratory by the Merrifield solid-phase
procedure, as previously described (Lopez Verrilli et al. 2009).
Peptide purity (> 97%) was confirmed by matrix assisted laser
desorption mass spectrometry. All other chemicals were analytical
grade reagents of the highest purity available.
Animals
Male Wistar-Kyoto (WKY) or SHR rats were used in our study. The
investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996).
Norepinephrine neuronal uptake
NE neuronal uptake was evaluated as previously described
(Gironacci et al. 2000) using the same experimental model where
we have previously evaluated Ang-(1–7) effects on NE release
(Gironacci et al. 2004a). Briefly, minced isolated hypothalami from
3-month-old male rats were incubated at 37C in Krebs solution (pH
7.4) continuously bubbled with 95% O2/5% CO2 in the absence
(basal) or presence of 0.1 or 1 lmol/L Ang-(1–7) during 5 min or
3 h, followed by the incubation with 125 pmol/L L-[7-3H]-NE (New
England Nuclear, Boston, MA, USA) during 5 min. The reaction
media also contain 100 lmol/L pargyline and 100 lmol/L hydro-
cortisone to avoid L-[7-3H]-NE degradation and non-neuronal
uptake, respectively. After four consecutive 15-min washes with
cool Krebs solution containing 15 lmol/L desipramine (to block
NET activity), tissues were homogenized, centrifuged and tritium
was quantified by liquid scintillation counting. NE neuronal uptake
was expressed as % of change with respect to basal conditions,
considering basal levels as 100%.
In another set of experiments, minced isolated hypothalami from
3-month-old male rats were incubated at 37C during 3 h in the
absence (basal) or presence of a specific anti-Ang-(1–7) antibody in
a concentration as previously reported (Höcht et al. 2008) (1/50)
and NE neuronal uptake was evaluated as described above. Anti-
Ang-(1–7) antibody was obtained from rabbit and previously
characterized to be specific for Ang-(1–7) (Lopez Verrilli et al.
2009).
Cell culture
Neuronal cultures were obtained from hypothalamus-brainstem
areas of 1-day-old rats, as previously 3described (Yu et al. 1996;
Lopez Verrilli et al. 2009). Cells were used after 8–10 days of the
initiation of culture. After 7 days, synapses between neurons as well
as synaptic vesicles in the pre-synaptic neuron were observed by
electron microscopy (data not shown).
Western blot
Protein expression was measured by western blot as previously
described (Lopez Verrilli et al. 2009). The following antibodies
were used: anti-NET (1/3000) (Santa Cruz Biotechnology Labora-
tories, Santa Cruz, CA, USA) or anti-Mas R (1/500) (Alomone,
Jerusalem, Israel) or anti-phosphospecific antibodies against Akt (1/
1000) (Cell Signaling) or ERK1/2 4(1/2000) (Cell Signaling). Total
Akt and ERK 1/2 protein content (non-phosphorylated) was
evaluated by reblotting membranes with anti-Akt (1/1000) or anti-
ERK 1/2 (1/2000) antibodies (Cell Signaling). Akt or ERK 1/2
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phosphorylation were normalized to protein content in the same
sample and expressed as % of change with respect to basal
conditions, considering basal levels as 100%. Protein loading was
evaluated by stripping and reblotting membranes with b-actin
antibody (1/1000) (Sigma Chemical Co.).
mRNA levels determination
Quantification of NET mRNA expression was performed by real-
time PCR and normalized by b-actin housekeeping gene expression.
Briefly, for cDNA synthesis, 2 lg of total RNA and 1 lg of random
hexamer primers (Promega Corp., Madison,5 WI, USA) were heated
at 70C for 5 min, followed by incubation at 4C. After adding 5 lL
of M-MLV6 RT 5· buffer (250 mmol/LTris–HCl, pH 8.3,
375 mmol/L KCl, 15 mmol/L MgCl2, 50 mmol/L dithiothreitol7 ),
25 U RNasin (Promega Corp.), 1.25 lL of 10 mmol/L dNTPs
(Invitrogen), and 200 U of MMLV reverse transcriptase (Promega
Corp.), the reaction was carried out at 37C for 1 h, followed by
inactivation of the enzyme at 95C for 10 min. Real-time PCR was
performed using a Bio-Rad iQ iCycler Detection System (Bio-Rad
Laboratories Ltd, CA, USA) with SYBER green fluorophore.
Reactions (in duplicates) were carried out in a total volume of
20 lL. A three-step protocol (95C for 20 s, 60C, annealing for
30 s, 72C for 40 s) was repeated for 40 cycles. Rat primers
(Invitrogen) were designed as previously described (Habecker et al.
2006):
(+)GCTGACCAGCACCATCAAC, (-)GGCGACATCCTCAAT
CTTGAC. A melt curve analysis was performed following every
run to ensure a single amplified product for every reaction. The
authenticity of the amplicon generated was confirmed by their size
in 2% agarose gel. In accordance with the literature, we did not find
any difference in the b-actin used as housekeeping gene, between
the experimental groups.
Statistical analysis
The data are presented as mean ± SEM. Statistical significance was
assessed by one-way analysis of variance (ANOVA) followed by
Bonferroni post-tests (GraphPad Prism 4; GraphPad Software, Inc.8 ).
p values < 0.05 were considered significant.
Results
Ang-(1–7) does not evoke acute effects on NE neuronal
uptake
As shown in Fig. 1, basal neuronal NE uptake was evaluated
in hypothalami from WKY and SHR rats. No difference was
observed between both strains. Incubation with 0.1 lmol/L
or 1 lmol/L Ang-(1–7) during 5 min, did not elicit any
change in neuronal NE uptake in hypothalami from SHR
(Fig. 1).
Ang-(1–7) increases NET expression through Mas receptor,
via Akt and ERK1/2-dependent pathways
Basal endogenous NET levels were similar in hypothalamic-
brainstem neuronal cultures from SHR and WKY (Fig. 2a).
A concentration of 0.1 lmol/L Ang-(1–7), chosen from
previous experiments (Gironacci et al. 2004a; Lopez Verrilli
et al. 2009), was used to test time-dependent effects on
neuronal cultures. Treatment of SHR neuronal cultures with
0.1 lmol/L Ang-(1–7) induced an increase in NET expres-
sion after 1–5 h of incubation (Fig. 2b).
Concentration–response assays were performed by incu-
bation of neuronal cultures with Ang-(1–7) during 3 h
(Fig. 2c). No effect on NET expression was observed with
0.01 lmol/L Ang-(1–7). Conversely, 0.1 and 1 lmol/L Ang-
(1–7) increased NET expression 40 ± 8% and 70 ± 24%
above basals, respectively (Fig. 2c).
Then, we investigated the Ang-receptor subtype that was
coupled to the stimulatory activity of Ang-(1–7) on NET
expression. Figure 3a shows that 1 lmol/L [D-Ala7]-Ang-(1–
7), a Mas receptor antagonist, blocked the stimulatory effect
of Ang-(1–7) on NET expression, suggesting the involve-
ment of Mas receptor. In fact, Mas R are expressed in
neuronal cultures from SHR and in a greater amount than that
in WKY (2.7-fold increase) (Fig. 3b). However, the effect of
Ang-(1–7) on NET expression was modified by neither
1 lmol/L PD123319, an AT2 receptor antagonist, nor
1 lmol/L losartan, an AT1 receptor antagonist (Fig. 3a),
demonstrating that AT1 or AT2 receptors are not involved in
the Ang-(1–7) stimulatory effect.
As it has been demonstrated that PI3 9-kinase/Akt and MEK
1/2 10-ERK 1/2 signal transduction pathways are coupled to
Mas receptor activation (Giani et al. 2007; Sampaio et al.
2007; Dias-Peixoto et al. 2008; 11Zimpelmann and Burns
Fig. 1 (a) Basal [3H]-NE neuronal uptake in hypothalami from WKY
and SHR rats as described in Methods. Results are expressed as
percentage of the response detected in hypothalami from WKY, taking
them as 100%. Data are means ± SEM of six experiments. (b) Effect
of Ang-(1–7) on [3H]-NE neuronal uptake in hypothalami from SHR.
Hypothalami were incubated with [3H]-NE in the absence (basal) or in
the presence of 0.1 lmol/L or 1 lmol/L Ang-(1–7) during 5 min and
NE neuronal uptake was measured as described in Methods. Results
are expressed as percentage of the response detected in basal con-
ditions, taking them as 100%. Data are mean ± SEM of 6–8 experi-
ments.
 2011 The Authors
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2009)12 we evaluated their involvement in the Ang-(1–7)-
stimulated NET expression. SHR neuronal cultures were
incubated with 0.1 lmol/L Ang-(1–7) during 3 h in the
presence of 25 lmol/L LY294002, a PI3-kinase inhibitor, or
10 lmol/L U0126, a MEK1/2 inhibitor. As shown in Fig. 3c,
Ang-(1–7)-stimulated NET expression was abolished when
PI3-kinase and MEK1/2 pathways were inhibited, suggesting
that Akt and ERK1/2 are both involved in Ang-(1–7) effect.
The inhibitors did not modify NET expression by them-
selves.
To verify that Ang-(1–7) induces activation of Akt and
ERK1/2 and that these effects are mediated via Mas receptor,
we assessed the effect of Ang-(1–7) on Akt and ERK1/2
phosphorylation in SHR neuronal cultures in the absence or
presence of [D-Ala7]-Ang-(1–7), a Mas receptor antagonist.
Following PI3-kinase stimulation, Akt becomes phosphory-
lated at Thr308 and Ser473, which results in its activation
(Alessi et al. 1996). As shown in Fig. 4a, 0.1 lmol/L Ang-
(1–7) increased Akt phosphorylation at Thr308, which was
maximal after 5 min of incubation. This effect was blocked
by 1 lmol/L [D-Ala7]-Ang-(1–7), a Mas receptor antagonist,
or by 25 lmol/L LY294002, a PI3-kinase inhibitor. These
results suggest that Ang-(1–7) activates Mas receptors, thus
leading to PI3-kinase activation with the subsequent Akt
phosphorylation at Thr308.
MEK1/2 are the kinases directly upstream of ERK1/2
responsible for the dual phosphorylation of ERK1/2 on
tyrosine and threonine residues and hence, its activation
(Pearson et al. 2001). Figure 4b shows that Ang-(1–7)
stimulated ERK1/2 phosphorylation after 10 min of incuba-
tion and this effect was abolished by 1 lmol/L [D-Ala7]-Ang-
(1–7), the Mas receptor antagonist, or 10 lmol/L U0126, the
MEK1/2 inhibitor. These results demonstrate that Ang-(1–7),
through Mas receptor activation, induced MEK1/2 activation
with the subsequent ERK1/2 phosphorylation.
Neither total Akt nor ERK1/2 contents were modified by
the different treatments (Fig. 4b).
Ang-(1–7) increases NET expression by stimulating NET
synthesis
As the increase in NET expression caused by Ang-(1–7) may
be due to an increase in NET synthesis, we examined the
effect of Ang-(1–7) on NET expression in the presence of
inhibitors of gene transcription and translation. The increase
in NET expression induced by 0.1 lmol/L Ang-(1–7) was
blocked by either actinomycin-D (0.5 and 1.0 lmol/L), a
gene transcription inhibitor, or cycloheximide (0.5 and
1.0 lmol/L), a protein synthesis inhibitor, suggesting that
Ang-(1–7) stimulates NET gene transcription and NET
mRNA translation (Fig. 5a and b). Dimethylsulfoxide (ac-
tynomycin solvent) did not modify NET expression by itself
(Fig. 5a).
To corroborate whether Ang-(1–7) induced a stimulatory
effect on NET de novo synthesis, we evaluated the effect of
the peptide on NET mRNA levels. As shown in Fig. 5c,
0.1 lmol/L Ang-(1–7) increased NET mRNA levels in
neuronal cultures after 3 h incubation.
Fig. 2 15(a) Basal expression of NET in both WKY and SHR hypotha-
lami-brainstem neuronal cultures. NET expression was measured by
western blot as described in Methods and is expressed as a per-
centage of the response detected in WKY cells, taking them as 100%.
Each bar represents the mean ± SEM of three determinations from six
separate cell culture preparations. (b) Time-dependent effect of Ang-
(1–7) on NET expression in hypothalami-brainstem neuronal cultures
from SHR. Neuronal cultures were incubated in the absence (control)
or presence of 0.1 lmol/L Ang-(1–7) for the indicated time periods.
NET expression was measured by western blot as described in
Methods and is expressed as the percentage of the response detected
in control cells, taking them as 100%. Each incubation period with
Ang-(1–7) had its respective control. The control band is shown only
once to simplify the graph. Each bar represents the mean ± SEM of
three determinations from five separate cell culture preparations.
* p < 0.05 as compared with the corresponding control. (c) Concen-
tration-response effect of Ang-(1–7) on NET expression in hypotha-
lami-brainstem neuronal cultures from SHR. Neuronal cultures were
incubated for 3 h with increasing concentrations of Ang-(1–7) (0.01–
1 lmol/L). NET expression was measured by western blot as de-
scribed in Methods and is expressed as a percentage of the response
detected in control cells, taking them as 100%. Data are mean ± SEM
of three determinations from four separate cell culture preparations.
*p < 0.05 as compared with control. A representative western blot is
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Fig. 316 (a) Effect of AT2-, AT1- and Mas receptor antagonists on the
Ang-(1–7)-stimulated NET expression in hypothalami-brainstem neu-
ronal cultures from SHR. Cells were incubated in the absence (control)
or presence of 0.1 lmol/L Ang-(1–7) during 3 h. When indicated the
AT2 receptor antagonist PD 123319 (AT2 antag) (1 lmol/L), or the
Mas receptor antagonist [D-Ala7]-Ang-(1–7) (Mas antag) (1 lmol/L), or
the AT1 receptor antagonist losartan (AT1 antag) (1 lmol/L) was ad-
ded alone or simultaneously with Ang-(1–7). NET expression was
measured by western-blot as described in Methods and is expressed
as a percentage of the response detected in control cells, taking them
as 100%. Each bar represents the mean ± SEM of three determina-
tions from five separate cell culture preparations. *p < 0.05 as com-
pared with control. A representative western blot is presented. (b) Mas
R expression in hypothalami-brainstem neuronal cultures from WKY
and SHR. Each bar represents the mean ± SEM of relative increase
over basal of three determinations from four separate cell culture
preparations. A representative western blot is presented. (c) Effect of
PI3-kinase and MEK1/2 inhibitors on the Ang-(1–7)-stimulated NET
expression in hypothalami-brainstem neuronal cultures from SHR.
Cells were incubated in the absence (control) or presence of 0.1 lmol/
L Ang-(1–7) during 3 h. When indicated, the MEK1/2 inhibitor U0126
(10 lmol/L), or the PI3-kinase inhibitor LY294002 (25 lmol/L) was
added alone or simultaneously with Ang-(1–7). NET expression was
measured by western blot as described in Methods and is expressed
as a percentage of the response detected in control cells, taking them
as 100%. Each bar represents the mean ± SEM of three determina-
tions from six separate cell culture preparations. *p < 0.05 as com-
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Fig. 417 Effect of Ang-(1–7) on Akt (a) and ERK 1/2 phosphorylation (b)
in SHR hypothalami-brainstem neuronal cultures. Left pannels. SHR
neuronal cultures were treated with 0.1 lmol/L Ang-(1–7) for 5–
15 min. Akt-phosphoThr308 (p-Akt) (a) or ERK 1/2-phosphoThr202/
Tyr204 (p-ERK 1/2) (b) were measured by western blot as described in
Methods and normalized to Akt and ERK 1/2 content in the same
sample. Results are expressed as the percentage of the response
detected in control cells, taking them as 100%. Each bar represents
the mean ± SEM of three determinations from five separate cell cul-
ture preparations. *p < 0.05 as compared with control. A representa-
tive western blot is presented. Right pannels. (a) SHR neuronal
cultures were incubated with Krebs buffer alone (control) or 0.1 lmol/L
Ang-(1–7) for 5 min. When indicated, the Mas receptor antagonist
1 lmol/L [D-Ala7]-Ang-(1–7) (Mas antag) or the PI3-kinase inhibitor
LY294002 (25 lmol/L) was simultaneously added with Ang-(1–7). (b)
SHR neuronal cultures were incubated with Krebs buffer alone (con-
trol) or 0.1 lmol/L Ang-(1–7) for 10 min. When indicated, the Mas
receptor antagonist 1 lmol/L [D-Ala7]-Ang-(1–7) (Mas antag) or the
MEK 1/2 inhibitor U0126 (10 lmol/L) was simultaneously added with
Ang-(1–7). Akt-phosphoThr308 (a) or ERK 1/2-phosphoThr202/Tyr204
(b) were measured by western blot as described in Methods and
normalized to Akt and ERK 1/2 content in the same sample. Total Akt
and ERK 1/2 abundance was measured by reblotting the same
membranes with anti-Akt or anti-ERK 1/2, respectively, and no chan-
ges were observed. Results are expressed as the percentage of the
response detected in control cells, taking them as 100%. Each bar
represents the mean ± SEM of 3 determinations from four separate
cell culture preparations. *p < 0.05 as compared with control. A rep-
resentative western blot is presented.
Fig. 5 18(a) Effect of Ang-(1–7) on NET expression in hypothalami-
brainstem neuronal cultures from SHR. Cells were incubated in the
absence (control) or presence of 0.1 lmol/L Ang-(1–7) during 3 h.
When indicated, the transcription inhibitor actinomycin-D (ACT-D 0.5
and 1.0 lmol/L) was added alone or simultaneously with Ang-(1–7).
NET expression was measured by western blot as described in
Methods and is expressed as a percentage of the response detected
in control cells, taking them as 100%. Each bar represents the
mean ± SEM of three determinations from five separate cell culture
preparations. *p < 0.05 as compared with control. A representative
western blot is presented. (b) Effect of Ang-(1–7) on NET expression
in hypothalami-brainstem neuronal cultures from SHR. Cells were
incubated in the absence (control) or presence of 0.1 lmol/L Ang-(1–
7) during 3 h. When indicated, the protein synthesis inhibitor cyclo-
heximide (CHX 0.5 and 1.0 lmol/L) was added alone or simulta-
neously with Ang-(1–7). NET expression was measured by western
blot as described in Methods and is expressed as a percentage of the
response detected in control cells, taking them as 100%. Each bar
represents the mean ± SEM of three determinations from four sepa-
rate cell culture preparations. *p < 0.05 as compared with control. A
representative western blot is presented. (c) Effect of Ang-(1–7) on
NET mRNA levels in hypothalami-brainstem neuronal cultures from
SHR. Cells were incubated in the absence (control) or presence of
0.1 lmol/L Ang-(1–7) during different times. NET mRNA was mea-
sured as described in Methods. Values are mean ± SEM and ex-
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Ang-(1–7) elicites a stimulatory long-term effect on
neuronal NE uptake
Considering that Ang-(1–7) increased NET expression
through Mas receptor stimulation (as shown in Figs 2 and
3a), we hypothesized that this effect would lead to a long-
term increase in neuronal NE uptake. To test this hypothesis,
we measured the effect of Ang-(1–7) on neuronal NE uptake
after 3 h of incubation, the period time after which Ang-(1–
7) induced an increase in NET expression and NET mRNA
levels. As shown in Fig. 6a, Ang-(1–7) (0.1 lmol/L) signif-
icantly increased NE neuronal uptake in hypothalami from
SHR, and this effect was abolished in the presence of either
1.0 lmol/L cycloheximide or the Mas receptor antagonist
(1.0 lmol/L).
Endogenous Ang-(1–7) contributes to NET up-regulation
To test whether endogenous Ang-(1–7) contributes to NE
neuronal uptake, hypothalami were incubated with a specific
anti-Ang-(1–7) antibody (Ab) and neuronal uptake was
evaluated 3 h later. As shown in Fig. 6b, when endogenous
Ang-(1–7) was blocked with the Ab, a decrease in NE
neuronal uptake was observed. In accord, when neuronal
cultures were incubated with the Ab during 3 h, a decrease in
NET expression was observed (Fig. 6c).
Altogether, these results confirm the long-term sympa-
toinhibitory effect of Ang-(1–7) via regulation of NET
expression.
Discussion
This study demonstrates that Ang-(1–7) does not evoke an
acute effect on neuronal NE uptake in hypothalami from
SHR. Conversely, Ang-(1–7) causes a long-term stimulatory
effect on NE neuronal uptake by increasing NET. Moreover,
Ang-(1–7)-stimulated NET expression is coupled to Mas
receptor activation acting through a PI3-kinase/Akt and
MEK 1/2-ERK1/2-dependent pathway.
NE release from the hypothalamic nuclei contributes to
blood pressure regulation by enhancing sympathetic nervous
system activity (De Wardener 2001). In this context, NE
uptake is an essential process that limits the action of NE and
prevents sympathetic overactivity. Thus, disturbances in
NET function are involved in the genesis and development of
hypertension (Bönisch and Brüss 2006). For instance, it has
been reported that the impaired uptake of NE by the NET
was closely related with the origin of essential hypertension
in a substantial number of patients (Esler et al. 1981;
Bönisch and Brüss 2006). In addition, a decrease in NE
uptake has been reported in cases of hypertension, orthostatic
intolerance and tachycardia (Esler et al. 1981; Hahn et al.
2003;13 Lambert et al. 2008). In all these situations, an
impaired NET function leads to disturbances of the homeo-
stasis of the sympathetic nervous system. Furthermore, a
genetic study has shown the association between the
presence of a variation in human NET promoter and essential
hypertension (Ono et al. 2003). Taking into account that
sympathetic overactivity results from an increase in synap-
tically released neurotransmitter, we may speculate that NET
Fig. 619 (a) Long-term effect of Ang-(1–7) on [3H]-NE neuronal uptake
in hypothalami from SHR. Hypothalami were incubated in the absence
(control) or in the presence of 0.1 lmol/L.Ang-(1–7) during 3 h and NE
neuronal uptake determined as described in Methods. When indi-
cated, the protein synthesis inhibitor cycloheximide (CHX) (1.0 lmol/
L) or the Mas receptor antagonist (Mas ant.) (1.0 lmol/L) were added
simultaneously with 0.1 lmol/L Ang-(1–7). Results are expressed as
percentage of the response detected in control conditions, taking them
as 100%. Data are means ± SEM of 6–8 experiments. *p < 0.05 as
compared with control. (b) [3H]-NE neuronal uptake in hypothalami
from SHR. Hypothalami were incubated for 3 h in the absence (con-
trol) or in the presence of a specific anti-Ang-(1–7) antibody (Anti-Ang
Ab) and NE neuronal uptake determined as described in Methods. (c)
NET expression in SHR hypothalami-brainstem neuronal cultures in
the absence (control) and presence of a specific anti-Ang-(1–7) anti-
body (Anti-Ang Ab). NET expression was measured by western blot as
described in Methods and is expressed as a percentage of the re-
sponse detected in control cells, taking them as 100%. Each bar
represents the mean ± SEM of three determinations from five sepa-















 2011 The Authors
Journal of Neurochemistry  2011 International Society for Neurochemistry, J. Neurochem. (2011) 10.1111/j.1471-4159.2011.07552.x























































activity should be augmented in a hypertensive state as a
compensatory feed back mechanism of control. However, Lu
et al. (1996) demonstrated that both basal NET activity and
NET mRNA levels are similar in brainstem, hypothalamus
and neuronal cultures from normotensive WKY and SHR. In
accordance, our present results show that the centrally basal
neuronal NE uptake and NET expression in central areas of
the sympathetic nervous system did not differ between SHR
and normotensive WKY rats. As an increase in NE release
and synthesis leads to sympathetic overactivity in SHR (De
Wardener 2001; Veerasingham and Raizada 2003), the fact
that NET activity and expression were not altered in this
hypertensive model (present results and Lu et al. 1996)
suggest that NET function may be disregulated, leading to
neurotransmitter accumulation. Another possible explanation
may be that an enhanced NE release and synthesis predom-
inates over NE uptake, and despite that Ang-(1–7) exerts a
counterbalancing effect (Gironacci et al. 2004a; Lopez
Verrilli et al. 2009; and present results), others pressor
agents act to favor the enhanced NE release and synthesis,
such as Ang II or endothelin-1 and -3 (Veerasingham and
Raizada 2003; Di Nunzio et al. 2004).
We have previously reported that Ang-(1–7) decreases NE
synthesis and release in hypothalami from SHR (Gironacci
et al. 2004a; Lopez Verrilli et al. 2009). This Ang-(1–7)-
induced NEmetabolism alterations result in a reduction of NE
availability into the synaptic cleft. Moreover, changes in the
transporter activity or expression should impact on the length
time and concentration of NE in the synaptic cleft. These
changes, in turn, may influence on pre- and post-synaptic
receptors, enhancing or diminishing the final response to the
released neurotransmitter. Ang-(1–7) did not evoke an acute
effect on neuronal NE uptake in hypothalami from SHR
(present results), neither in hypothalami from normotensive
rats (Gironacci et al. 2000). Conversely, Ang-(1–7) evoked a
long-term effect on NE neuronal uptake by increasing NET
expression (present results). The fact that this effect was
cycloheximide-sensitive and that Ang-(1–7) induced an
increase in NET mRNA levels demonstrates that Ang-(1–7)
long-term stimulation of neuronal NE uptake involves an
increase in mRNA translation and/or stability. Cycloheximide
has been reported not only to inhibit protein translation but also
to increase mRNA stabilization (Yamazaki and Takeshige
2008). In agreement, Apparsundaram et al. (2001) described a
similar action for insulin: no acute effect on NE neuronal
uptake but a long-term action on that mechanism involving an
increase in NET biosynthesis. Our results about the inhibitory
role of Ang-(1–7) on the NET system were reinforced by the
fact that when endogenous Ang-(1–7) was blocked by its
specific antibody, a decrease in NE neuronal uptake as well as
in NET expression were observed.
Ang-(1–7) long-term stimulation of neuronal NE uptake
involves an increase in NET mRNA translation and/or
stability after 3 h, whereas at a shorter time (1 h), Ang-(1–7)
may induce a decrease in NET protein degradation. The fact
that the time course of NET protein and mRNA expression is
not the same may be due to a decrease in NET protein
degradation induced by Ang-(1–7). For instance, Ang-(1–7)
affects tyrosine hydroxylase expression by regulating its
turnover (Lopez Verrilli et al. 2009). Tyrosine hydroxylase
is the rate-limiting enzyme involved in norepinephrine
synthesis.
Taking into account that Ang-(1–7) opposes many of Ang
II actions, including NE release and synthesis (Veerasingham
and Raizada 2003; Gironacci et al. 2004a; Lopez Verrilli
et al. 2009; Xu et al. 2011) it was surprising to find that Ang-
(1–7) effect on NET expression was similar to that displayed
by Ang II (Lu et al. 1996). Lu et al. (1996) showed that Ang
II stimulates the NET system both acutely and chronically in
neuronal cultures from SHR, the former involving activation
of pre-existing transporters and the latter involving NET gene
transcription and translation. As Ang II is degraded to Ang-
(1–7) by ACE2 14activity (Ferrario et al. 2010; Ferreira et al.
2010; Xu et al. 2011), we could not disregard that the effect
of Ang II on NET system may be mediated by Ang-(1–7)
generation. For instance, it has been shown that some of the
central or renal effects of Ang II are caused by Ang III
generation (Wright et al. 2003; Padia et al. 2008). Further
experiments should be carried out to test this hypothesis.
Post-translational modifications such as glycosylation and
phosphorylation regulate monoamine transporter function
and expression levels (Mandela and Ordway 2006; Rama-
moorthy et al. 2011). PI3-kinase pathways are known to
regulate long-term expression of neurotransmitter transport-
ers, including monoamine transporters (Ramamoorthy et al.
2011). NET has also been shown to be regulated by MAPK
(Mandela and Ordway 2006; Ramamoorthy et al. 2011).
Conversely, protein phosphatase 1/2A down-regulates NET,
dopamine and serotonin transporters activity (Mandela and
Ordway 2006; Ramamoorthy et al. 2011). Thus, direct
phosphorylation and/or dephosphorylation of transporters
by cellular protein kinases and phosphatases are involved in
the dynamic regulation and expression of amine transporters.
Our present work shows that the long-term stimulatory effect
of Ang-(1–7) on NET expression was coupled to Mas
receptor activation acting through a PI3-kinase/Akt and
MEK1/2-ERK1/2 mediated pathways. The involvement of
PI3-kinase/Akt and MEK1/2-ERK1/2 signaling cascades
have been described for Ang II on NE neuromodulation in
neuronal cultures from SHR (Gelband et al. 1997; Yang and
Raizada 1999). In this way, Ang-(1–7) appears to share a
similar response and pathway as Ang II. It must be pointed
out that Ang-(1–7)-induced Akt or ERK1/2 phosphorylation
mediated by Mas receptors has been previously reported at
the perypheral level (Giani et al. 2007; Sampaio et al. 2007;
Dias-Peixoto et al. 2008; Zimpelmann and Burns 2009) but
not centrally, not even in neurons, where Mas receptors are
expressed (present results).. Furthermore, an increased Mas R
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expression of 2.7-fold was observed in hypothalami-brain
stem neurons from SHR compared with WKY (present
results). This increase may be due to compensate the
increased Ang II activity observed in SHR (Gelband et al.
1997; Veerasingham and Raizada 2003). In addition, AT1
receptors have been reported to be increased in neuronal
cultures from SHR, being 4-fold higher than the correspond-
ing WKY cultures (Raizada et al. 1993).
Despite the fact that it has been shown that the PI3K/Akt
pathway is involved in the stimulatory action of Ang-(1–7)
on NO generation (Sampaio et al. 2007; Dias-Peixoto et al.
2008) and that the inhibitory effect of Ang-(1–7) on NE
release is mediated by NO (Gironacci et al. 2004a), we
disregard that the Ang-(1–7)-stimulated NET expression may
be coupled to NO production, because evidences show that
NO reduces NE uptake (Kaye et al. 2000; Hope et al. 2010),
in contrast to what is observed with Ang-(1–7) (present
results). Up-to-date effects of NO on NET have not been
fully characterized yet.
Amine transporters are essential players in regulating
normal and abnormal amine signaling in the CNS and
periphery, fine-tuning neurotransmitter levels at the synaptic
cleft. Altered pattern or a disturbance in the pre- and post-
synaptic regulatory mechanisms could lead to abnormal
neurotransmission and hence abnormal behavior, brain dis-
orders or hypertension. Present results demonstrate that Ang-
(1–7) does not evoke an acute but a long-term effect on NE
neuronal uptake in hypothalami from SHR increasing NET
expression, being these effects coupled to Mas receptor
activation acting through both MEK1/2-ERK1/2 and PI3-
kinase/Akt dependent pathways. In this way, Ang-(1–7) may
regulate a pre-synaptic mechanism in maintaining appropriate
synaptic NE levels during hypertensive conditions. This
study, together with the fact that Ang-(1–7) inhibits NE
synthesis and release from SHR hypothalami supports a
negative neuromodulatory role for Ang-(1–7) on central
sympathetic nervous system activity, thus contributing to the
modulation of NE homeostasis. Enhanced sympathetic activ-
ity and hypertension are often associated with an activation of
the brain RAS. A better understanding of the interaction
between these central networks, peptides and monoamines
that regulate sympathetic effluents might offer new possibil-
ities for pharmacological intervention in hypertension.
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Central NET upregulation by angiotensin-(1-7) in hypertension
As angiotensin (Ang) (1–7) decreases norepinephrine (NE) content in the synaptic cleft, we investigated the effect of Ang-(1–7)
on centrally NE neuronal uptake, the main mechanism for NE removal from the synaptic cleft, in hypothalamic neurons from
hypertensive rats. We showed that Ang-(1–7) 20causes a long-term stimulatory effect on NE neuronal uptake by increasing NE
transporter expression. This effect is coupled to Mas receptor activation acting through both MEK1/2-ERK1/2 and PI3-kinase/
Akt-dependent pathways. In this way, Ang-(1–7) may regulate a pre-synaptic mechanism in maintaining appropriate synaptic

















 2011 The Authors
Journal of Neurochemistry  2011 International Society for Neurochemistry, J. Neurochem. (2011) 10.1111/j.1471-4159.2011.07552.x



























































During the copy-editing of your paper, the following queries arose. Please respond to these by marking up your
proofs with the necessary changes/additions. Please write your answers on the query sheet if there is insufficient
space on the page proofs. Please write clearly and follow the conventions shown on the attached corrections
sheet. If returning the proof by fax do not write too close to the paper’s edge. Please remember that illegible
mark-ups may delay publication.
Many thanks for your assistance.
Query reference Query Remarks
1 AUTHOR: Please check and confirm that the graphical abstract is fine for
publication.
2 AUTHOR: Bönish and Brüss 2006 has been changed to Bönisch and Brüss
2006 so that this citation matches the Reference List. Please confirm that
this is correct.
3 AUTHOR: Yu et al. 1998 has been changed to Yu et al. 1996 so that this
citation matches the Reference List. Please confirm that this is correct.
4 AUTHOR: Please define abbreviation ERK1/2 here in the text and also
insert in the abbreviation list.
5 AUTHOR: Please check the city name for Promega Corp.
6 AUTHOR: It is journal style for abbreviations which are used less than
three times to be fully spelt out. Please define abbreviation M-MLV here in
the text.
7 AUTHOR: As per journal style, abbreviation [DTT] mentioned less than
three times in the article is expanded in full. If expansion incorrect, please
insert correct expansion.
8 AUTHOR: Please give address information for GraphPad Software, Inc.:
town, state (if applicable), and country.
9 AUTHOR: Please define abbreviation PI3 here in the text and also insert in
the abbreviation list.
10 AUTHOR: Please define abbreviation MEK 1/2 here in the text and also
insert in the abbreviation list.
11 AUTHOR: Dias Peixoto et al. 2008 has been changed to Dias-Peixoto et al.
2008 so that this citation matches the Reference List. Please confirm that
this is correct.
12 AUTHOR: Zimpelmann et al. 2009 has been changed to Zimpelmann and
Burns 2009 so that this citation matches the Reference List. Please confirm
that this is correct.
13 AUTHOR: Han et al. 2003 has been changed to Hahn et al. 2003 so that
this citation matches the Reference List. Please confirm that this is correct.
14 AUTHOR: It is journal style for abbreviations which are used less than
three times to be fully spelt out. Please define abbreviation ACE2 here in
the text.
15 AUTHOR: Figure 2 has been saved at a low resolution of 179 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/submit_illust.asp?site=1
16 AUTHOR: Figure 3 has been saved at a low resolution of 197 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/submit_illust.asp?site=1
17 AUTHOR: Figure 4 has been saved at a low resolution of 185 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/submit_illust.asp?site=1
18 AUTHOR: Figure 5 has been saved at a low resolution of 182 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/submit_illust.asp?site=1
19 AUTHOR: Figure 6 has been saved at a low resolution of 189 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/submit_illust.asp?site=1
20 AUTHOR: GA has been saved at a low resolution of 145 dpi. Please
resupply at 600 dpi. Check required artwork specifications at http://
authorservices.wiley.com/submit_illust.asp?site=1
 
USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION  
 
Required software to e-Annotate PDFs: Adobe Acrobat Professional or Adobe Reader (version 8.0 or 
above). (Note that this document uses screenshots from Adobe Reader X) 
The latest version of Acrobat Reader can be downloaded for free at: http://get.adobe.com/reader/ 
 





























































1. Replace (Ins) Tool Î for replacing text. 
 
Strikes a line through text and opens up a text 
box where replacement text can be entered. 
How to use it 
‚ Highlight a word or sentence. 
‚ Click on the Replace (Ins) icon in the Annotations 
section. 
‚ Type the replacement text into the blue box that 
appears. 
This will open up a panel down the right side of the document. The majority of 
tools you will use for annotating your proof will be in the Annotations section, 
rkevwtgf"qrrqukvg0"YgÓxg"rkemgf"qwv"uqog"qh"vjgug"vqqnu"dgnqy< 
 
2. Strikethrough (Del) Tool Î for deleting text. 
 
Strikes a red line through text that is to be 
deleted. 
How to use it 
‚ Highlight a word or sentence. 





3. Add note to text Tool Î for highlighting a section 
to be changed to bold or italic. 
 
Highlights text in yellow and opens up a text 
box where comments can be entered. 
How to use it 
‚ Highlight the relevant section of text. 
‚ Click on the Add note to text icon in the 
Annotations section. 
‚ Type instruction on what should be changed 
regarding the text into the yellow box that 
appears. 
4. Add sticky note Tool Î for making notes at 
specific points in the text. 
 
Marks a point in the proof where a comment 
needs to be highlighted. 
How to use it 
‚ Click on the Add sticky note icon in the 
Annotations section. 
‚ Click at the point in the proof where the comment 
should be inserted. 






















































For further information on how to annotate proofs, click on the Help menu to reveal a list of further options: 
5. Attach File Tool Î for inserting large amounts of 
text or replacement figures. 
 
Inserts an icon linking to the attached file in the 
appropriate pace in the text. 
How to use it 
‚ Click on the Attach File icon in the Annotations 
section. 
‚ Enkem"qp"vjg"rtqqh"vq"yjgtg"{qwÓf"nkmg"vjg"cvvcejgf"
file to be linked. 
‚ Select the file to be attached from your computer 
or network. 
‚ Select the colour and type of icon that will appear 
in the proof. Click OK. 
6. Add stamp Tool Î for approving a proof if no 
corrections are required. 
 
Inserts a selected stamp onto an appropriate 
place in the proof. 
How to use it 
‚ Click on the Add stamp icon in the Annotations 
section. 
‚ Select the stamp you want to use. (The Approved 
stamp is usually available directly in the menu that 
appears). 
‚ Enkem"qp"vjg"rtqqh"yjgtg"{qwÓf"nkmg"vjg"uvcor"vq"
appear. (Where a proof is to be approved as it is, 
this would normally be on the first page). 
7. Drawing Markups Tools Î for drawing shapes, lines and freeform 
annotations on proofs and commenting on these marks. 
Allows shapes, lines and freeform annotations to be drawn on proofs and for 
comment to be made on these marks.. 
 
How to use it 
‚ Click on one of the shapes in the Drawing 
Markups section. 
‚ Click on the proof at the relevant point and 
draw the selected shape with the cursor. 
‚ To add a comment to the drawn shape, 
move the cursor over the shape until an 
arrowhead appears. 
‚ Double click on the shape and type any 
text in the red box that appears. 
